3 Questions
What is the recommended action if a patient receiving trastuzumab therapy experiences a decrease in LVEF?
Withhold trastuzumab therapy and reassess LVEF after four weeks
Which of the following factors increases the risk of trastuzumab cardiotoxicity?
Previous or concurrent use of taxanes
What is the recommended treatment for trastuzumab-induced heart failure?
Standard heart failure medication
Study Notes
- Trastuzumab cardiotoxicity can cause a decrease in LVEF and clinical heart failure.
- Symptoms of heart failure have been reported in 3-7% of patients receiving trastuzumab.
- Age, previous or concurrent anthracycline use, and obesity are risk factors for trastuzumab cardiotoxicity.
- Cardiac function monitoring is recommended for patients receiving anthracyclines and trastuzumab.
- Patients should be counseled on reducing cardiovascular risk through lifestyle changes.
- Standard heart failure medication is recommended for trastuzumab-induced heart failure.
- Trastuzumab therapy should be withheld and LVEF reassessed after four weeks.
- If LVEF remains low, trastuzumab should be discontinued.
- Prophylactic use of beta blockers or ACEi/ARB may be beneficial for high-risk patients.
- Cardiac biopsy specimens do not show significant myocyte destruction.
Test your knowledge on trastuzumab and its potential cardiotoxicity with this informative quiz. Explore the incidence, risk factors, and management of trastuzumab-induced heart failure. Learn about the importance of cardiac function monitoring, lifestyle changes, and standard heart failure medication. Discover the benefits and limitations of prophylactic use of beta blockers or ACEi/ARB in high-risk patients. Take this quiz to enhance your understanding of trastuzumab cardiotoxicity and its implications for
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
